Link to this page
Biological and Environmental Research Ontology
| Preferred Name | Alemtuzumab | |
| Synonyms |
|
|
| Definitions |
A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04) |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C1681 |
|
| Accepted_Therapeutic_Use_For |
Chronic Lymphocytic Leukemia (CLL)
|
|
| ALT_DEFINITION |
A type of monoclonal antibody used in the treatment of leukemia. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.
|
|
| CAS_Registry |
216503-57-0
|
|
| code |
C1681
|
|
| Contributing_Source |
CTRP FDA
|
|
| definition |
A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)
|
|
| Display_Name |
Alemtuzumab
|
|
| FDA_UNII_Code |
3A189DH42V
|
|
| Has_Target | ||
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 |
|
| Is_Value_For_GDC_Property | ||
| label |
Alemtuzumab
|
|
| Legacy Concept Name |
Alemtuzumab
|
|
| Maps_To |
Alemtuzumab
|
|
| NCI_Drug_Dictionary_ID |
37783
|
|
| NSC Number |
715969
|
|
| PDQ_Closed_Trial_Search_ID |
37783
|
|
| PDQ_Open_Trial_Search_ID |
37783
|
|
| Preferred_Name |
Alemtuzumab
|
|
| prefixIRI |
NCIT:C1681
|
|
| prefLabel |
Alemtuzumab
|
|
| Semantic_Type |
Amino Acid, Peptide, or Protein Pharmacologic Substance Immunologic Factor
|
|
| UMLS_CUI |
C0383429
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |